Abstract: A method for treating a disorder characterized by excessive cell proliferation in a patient by administering to the patient a therapeutically effective amount of sclareolide.

Abstract: The invention is drawn to antisense oligonucleotides directed to the inhibition of the IgE receptor synthesis.

Abstract: The invention relates to oligonucleotides and their derivatives to inhibit the expression of isoprenyl protein transferases, therapeutic compositions containing such compounds and the use of such compositions of oligonucleotides for the treatment or therapy of diseases of the human or animal body induced by an abnormal and/or uncontrolled cellular proliferation.

Abstract: The invention relates to a method of treating and a therapeutical composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS) and related infections. The composition comprises from 1 to 100% of a complex of Poly(A).Poly(U), preferably associated with other anti-AIDS coagents which act on the HIV virus according to a different mechanism from that of the complex of Poly(A).Poly(U). The composition is suitably administered in 100 to 4,000 mg doses and at 3 to 5 day intervals.

Abstract: A method of promoting regeneration of hemopoietic cells in a subject undergoing chemotherapy or radiotherapy, which method includes the steps of (i) administering to the subject a first amount of AcSDKP or an agonist thereof, the first amount being effective to reduce the proliferation of hemopoietic cells during the chemotherapy or radiotherapy; (ii) administering to the subject a second amount of an angiotensin-converting enzyme (ACE) inhibitor, said second amount being effective to reduce the degradation of said AcSDKP or an agonist thereof by angiotensin-converting enzyme; and (iii) after the chemotherapy or radiotherapy, administering to the subject a second amount of a hemopoiesis growth factor, the second amount being effective to stimulate the proliferation of hemopoietic cells.

Abstract: The invention relates to a method of treating and a therapeutical composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS) and related infections. The composition comprises from 1 to 100% of a complex of Poly(A).Poly(U), preferably associated with other anti-AIDS coagents which act on the HIV virus according to a different mechanism from that of the complex of Poly(A).Poly(U). The composition is suitably administered in 100 to 4000 mg doses and at 3 to 5 day intervals.

Abstract: An injection device for intramuscular or subcutaneous injection of solid or semi-solid medicaments is disclosed. The device includes main body member having a needle attached thereto. A protective sleeve covers the needle and retracts into the main body member when the device is pressed against the skin of a patient. A plunger with an attached rod maintains the medicament in the patient as the needle is withdrawn.

Abstract: Peptides derived from the C terminal sequence of sorbin, but containing at least one D-amino acid residue, inhibit pepsin release and are therefore likely to be useful in the treatment of ulcers or oesophagitis. Their salts and substitution derivatives are also claimed as a pharmaceutical compositions containing them. A method for the treatment of a patient suffering from gastric ulcers or oesophagitis comprising the administration of said peptides, is also claimed.

Abstract: The invention features an implantable device for the automatic delivery of an active ingredient according to an adjustable delivery profile. The device includes a housing; a reservoir operatively connected to the housing and arranged to store a solid composition including the active ingredient; an actuator arranged within the housing to move the solid composition from the reservoir to a transit area, wherein the solid composition exits the housing at the transit area; a controller that acts on the actuator to adjust movement of the solid composition out of the housing according to the adjustable delivery profile; and a power source arranged to provide energy to the actuator and the controller. The solid composition can be an elongate, solid composition comprising a drug, and up to 90% of a carrier, wherein the composition has a cross-section of less than 0.

Abstract: A two-step process for converting ginkgolide C into ginkgolide B is disclosed. In the first step, ginkgolide C is reacted with a sulfonic anhydride to obtain a C-7 sulfonate of ginkgolide C. In the second step, the C-7 sulfonate of ginkgolide C is reacted with a borohydride, and this reaction eliminates the C-7 radical of the C-7 sulfonate of ginkgolide C, thus producing ginkgolide B.

Abstract: A method of making microballs is disclosed. An active ingredient, a biocompatible polymer and a supporting phase, such as silicone oil, are stirred at a temperature above the Tg of the polymer and below the temperature at which any of the ingredients vaporizes or degrades. Stirring is continued until microballs of the desired diameter are formed, whereafter the mixture is cooled and the microballs are separated from the supporting phase. The microballs are substantially spherical, substantially smooth on their external surface and have substantially no active ingredient on their external surface.

Abstract: The invention relates to thieno-triazolo-diazepine derivatives of the formula: ##STR1## wherein Y stands for oxygen or sulphur and R stands for various substituents, to a preparation process of said compounds and to therapeutic compositions containing the same. The compounds are particularly interesting as anti-asthmatic, anti-allergic and gastro-intestinal protectors.

Abstract: The invention relates to compounds of the general formula AB, which may be a salt or an amide, wherein:A represents a cyclooxygenase inhibitor having an accessible acidic function andB represents the L-form of arginine analogues of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 represent various substituents, process for the preparation of such compounds and pharmaceutical composition thereof.

Abstract: The invention relates to a N-(2,4- or 2,5-disubstituted tetrahydrofuryl alkyl)-N-(phenylethyl-.beta.-ol)amine derivative, under a racemic or enantiomer form, of general formula I ##STR1## wherein R represent various radicals and n is of from 1 to 10, to a process for the preparation of said derivative, and to pharmaceutical compositions comprising the same.

Abstract: The invention relates to compounds of the general formula AB, which may be a salt or an amide, wherein:A represents a cyclooxygenase inhibitor having an accessible acidic function andB represents the L-form of arginine analogues of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 represent various substituents, process for the preparation of such compounds and pharmaceutical composition thereof.

Abstract: The invention relates to benzofuranylimidazole derivatives of the general formula (1) ##STR1## wherein R.sub.1 and R.sub.2 represent various radicals, to a process for their preparation and to pharmaceutical compositions containing them.

Abstract: The invention relates to benzofuranylimidazole derivatives of the general formula (1) ##STR1## wherein R.sub.1 and R.sub.2 represent various radicals, to a process for their preparation and to pharmaceutical compositions containing them.

Abstract: An osmotic pump comprises a housing (2) within which is a delivery chamber (5) separated from an osmotic salt chamber (7) by impermeable moveable pressure responsive means such as a piston (6) or a flexible membrane. The osmotic salt chamber (7) is separated from a source of osmotic fluid, e.g. an osmotic fluid chamber (12), by a semipermeable membrane (96,36), optionally mounted in a piston (9,23). A fluid barrier isolates the osmotic salt chamber (7) from the source of osmotic fluid for storage of the pump, and may be inactivated when the pump is to be used. The fluid barrier may be a foil sheet (10), inactivatable by rupture, or a piston and a fluid bypass arrangement (21,23). Activation of the osmotic pump may be effected in some embodiments by loading the discharge chamber (5) with the agent to be delivered and in other embodiments by movement of a plunger (16), under manual control or, if the plunger is pre-biassed, by release of a locking means (18) which holds it in position.

Abstract: The invention relates to a process for the preparation of ginkgolide B from ginkgolide C and to ginkgolide B thus obtained, the process comprising the following succession of four steps:protecting the 10-hydroxy group of ginkgolide C by conversion to an alkyl ester, the reaction being effected in dimethylformamide at a temperature of from 15.degree. to 50.degree. C. for from 4 to 10 hours;activating the 7-hydroxy group of the resultant 10-protected ginkgolide C by conversion to a (R)thiocarbonyl ester, the activation being effected in basic conditions at a temperature of from 0.degree. to 40.degree. C. for from 1 to 24 hours;deoxygenating the 7-activated group in the resultant 10-protected 7-activated ginkgolide C by treating it with tributyltin hydride or tris-(trimethylsilyl)silane, in an aprotic solvent, in the presence of a free-radical generator, the reaction being effected at a temperature of from 70.degree. to 110.degree. C.

Abstract: The invention relates to a preparation process of particles designed to release an effective amount of active ingredient over a predetermined period of time, said particles comprising one ore more active ingredients in admixture with a bioresorbable and/or biodegradable polymer or copolymer, and the particles thus obtained in a substantially spheroidal form and substantially deprived of active ingredient on the external covering.